Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
作者信息
Moslehi Javid J, Salem Joe-Elie, Sosman Jeffrey A, Lebrun-Vignes Bénédicte, Johnson Douglas B
机构信息
Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Division of Oncology, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; Cardio-Oncology Program, Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA; AP-HP, Pitié-Salpêtrière Hospital, Department of Pharmacology, CIC-1421, Pharmacovigilance Unit, INSERM, UMR ICAN 1166, Sorbonne Universités, UPMC Univ Paris 06, Faculty of Medicine, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France.
出版信息
Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.
Abstract
摘要
相似文献
1
Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis.
Lancet. 2018 Mar 10;391(10124):933. doi: 10.1016/S0140-6736(18)30533-6.
2
Recurrent Myocarditis Induced by Immune-Checkpoint Inhibitor Treatment Is Accompanied by Persistent Inflammatory Markers Despite Immunosuppressive Treatment.
JCO Precis Oncol. 2021 Mar 11;5. doi: 10.1200/PO.20.00370. eCollection 2021 Mar.
3
Immune checkpoint inhibitors-related myocarditis in patients with cancer: an analysis of international spontaneous reporting systems.
BMC Cancer. 2021 Jan 7;21(1):38. doi: 10.1186/s12885-020-07741-0.
4
A retrospective study of immune checkpoint inhibitor-associated myocarditis in a single center in China.
Chin Clin Oncol. 2020 Apr;9(2):16. doi: 10.21037/cco.2020.03.08. Epub 2020 Apr 7.
5
Fatal Case of Immune-Related Myocarditis and Myositis Due to Treatment with Immune Checkpoint and Tyrosine Kinase Inhibitors.
Acta Med Port. 2024 Dec 2;37(12):865-868. doi: 10.20344/amp.21306. Epub 2024 Oct 14.
6
Association between myocarditis and other immune-related adverse events secondary to immune checkpoint inhibitor use.
Int J Cancer. 2020 Sep 15;147(6):1753-1754. doi: 10.1002/ijc.32960. Epub 2020 May 6.
7
Progressed Atrioventricular Block in Immune Checkpoint Inhibitor Induced Myocarditis: A Case Report.
Pacing Clin Electrophysiol. 2025 Apr;48(4):414-417. doi: 10.1111/pace.15155. Epub 2025 Feb 6.
8
Immune checkpoint inhibitor-associated myocarditis: manifestations and mechanisms.
J Clin Invest. 2021 Mar 1;131(5). doi: 10.1172/JCI145186.
9
An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Biomolecules. 2021 May 22;11(6):785. doi: 10.3390/biom11060785.
10
Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor-Associated Myocarditis.
Circulation. 2020 Jun 16;141(24):2031-2034. doi: 10.1161/CIRCULATIONAHA.119.044703. Epub 2020 Jun 15.
引用本文的文献
1
Real-Life Management of Elevated Troponin Level in Patients Treated with Immune Checkpoint Inhibitors.
CJC Open. 2025 Feb 13;7(8):1075-1082. doi: 10.1016/j.cjco.2025.02.005. eCollection 2025 Aug.
2
Using plasma cell-free mRNA to profile immune response and myocardial damage in immune checkpoint inhibitor-induced myocarditis.
J Clin Invest. 2025 Aug 15;135(16). doi: 10.1172/JCI188817.
3
Case With Refractory Myasthenia Gravis Caused by Pembrolizumab.
J Community Hosp Intern Med Perspect. 2025 May 5;15(3):59-62. doi: 10.55729/2000-9666.1486. eCollection 2025.
4
Prognostic Value of Biomarkers in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.
JACC Adv. 2025 Jul 31;4(9):102022. doi: 10.1016/j.jacadv.2025.102022.
5
Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitors: Interpreting the Discrepancy Between Clinical Trials and Real-World Data.
Cureus. 2025 Jun 30;17(6):e87049. doi: 10.7759/cureus.87049. eCollection 2025 Jun.
6
Immunotherapy-Induced Cardiotoxicity: A Narrative Review of Real-World Case Reports, Recent Information and Clinical Evidence.
Cardiovasc Toxicol. 2025 Jul 13. doi: 10.1007/s12012-025-10038-y.
7
Cardiovascular adverse effects of immunotherapy in cancer: insights and implications.
Front Oncol. 2025 Jun 18;15:1601808. doi: 10.3389/fonc.2025.1601808. eCollection 2025.
8
Cardiotoxicity in cancer immunotherapy: a systematic review and global meta-analysis.
J Transl Med. 2025 Jul 1;23(1):718. doi: 10.1186/s12967-025-06768-w.
9
The predictive value of serial troponin measurements in patients treated with immune checkpoint inhibitors.
Oncologist. 2025 Jun 4;30(6). doi: 10.1093/oncolo/oyaf147.
10
Immune-Related Fulminant Myocarditis Revealed Using Myocardial Histopathology at Autopsy in the Treatment of Advanced Renal Cell Carcinoma: A Case Report.
Case Rep Oncol. 2025 May 7;18(1):738-743. doi: 10.1159/000546288. eCollection 2025 Jan-Dec.
本文引用的文献
1
Clinical Features, Management, and Outcomes of Immune Checkpoint Inhibitor-Related Cardiotoxicity.
Circulation. 2017 Nov 21;136(21):2085-2087. doi: 10.1161/CIRCULATIONAHA.117.030571.
2
Fulminant Myocarditis with Combination Immune Checkpoint Blockade.
N Engl J Med. 2016 Nov 3;375(18):1749-1755. doi: 10.1056/NEJMoa1609214.
3
Cardiotoxicity associated with CTLA4 and PD1 blocking immunotherapy.
J Immunother Cancer. 2016 Aug 16;4:50. doi: 10.1186/s40425-016-0152-y. eCollection 2016.
4
PD-1 Blockers.
Cell. 2015 Aug 27;162(5):937. doi: 10.1016/j.cell.2015.07.045.
Zotero 插件